# US 2025/0145618 A1 · Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145618 A1
- Document ID: US20250145618A1
- Status: Published application
- Kind: A1
- Application number: 18/722,486
- Filed: 2022-12-20
- Published: 2025-05-08
- Earliest claimed: 2021-12-21
- Assignees: Principia Biopharma Inc.
- Applicants: Principia Biopharma Inc.; Genzyme Corporation
- Inventors: Tim Owens; Philippe Eric Ochsenbein; Krista Diaz
- Web page: https://patentgrep.com/patent/US20250145618A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to crystalline forms of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one free base and HCl salt thereof.

## Claims

### Claim 1

A substantially crystalline compound of Formula (1)

### Claim 2 (depends on 1)

The substantially crystalline compound of claim 1, wherein the compound of Formula (1) is Form 1.

### Claim 3 (depends on 2)

The substantially crystalline compound of claim 2, wherein the compound of Formula (1) Form 1 is characterized by an XRPD pattern substantially the same as FIG. 1.

### Claim 4 (depends on 3)

The substantially crystalline compound of claim 3, wherein the compound of Formula (1) Form 1 is characterized by an XRPD pattern comprising one or more peaks chosen from peaks at about 7.66° 2θ, 7.86° 2θ, 10.03° 2θ, 10.51° 2θ, 10.97° 2θ, 11.99° 2θ, 13.19° 2θ, 13.59° 2θ and 13.96° 2θ.

### Claim 5 (depends on 1)

The substantially crystalline compound of claim 1, wherein the compound of Formula (1) is Form 2.

### Claim 6 (depends on 5)

The substantially crystalline compound of claim 5, wherein the compound of Formula (1) Form 2 is characterized by an XRPD pattern substantially the same as FIG. 2.

### Claim 7 (depends on 3)

The substantially crystalline compound of claim 3, wherein the compound of Formula (1) Form 2 is characterized by an XRPD pattern comprising one or more peaks chosen from peaks at about 4.15° 2θ, 10.22° 2θ, 10.41° 2θ, 11.03° 2θ, 14.41° 2θ, 14.85° 2θ, 15.63° 2θ, 16.55° 2θ and 17.73° 2θ.

### Claim 8

A substantially crystalline form of a compound of Formula (1)·HCl.

### Claim 9 (depends on 8)

The substantially crystalline compound of claim 8, wherein the compound of Formula (1)·HCl is Form 1.

### Claim 10 (depends on 9)

The substantially crystalline compound of claim 9, wherein the compound of Formula (1)·HCl Form 1 is characterized by an XRPD pattern substantially the same as FIG. 5.

### Claim 11 (depends on 9)

The substantially crystalline compound of claim 9, wherein the compound of Formula (1)·HCl Form 1 is characterized by an XRPD pattern comprising one or more peaks chosen from peaks at about 6.309° 2θ, 9.480° 2θ, 10.933° 2θ, 12.261° 2θ, 12.647° 2θ, 14.482° 2θ, 14.918° 2θ, 16.253° 2θ and 16.425° 2θ.

### Claim 12 (depends on 8)

The substantially crystalline compound of claim 8, wherein the compound of Formula (1)·HCl is Form 2.

### Claim 13 (depends on 12)

The substantially crystalline compound of claim 12, wherein the compound of Formula (1)·HCl Form 2 is characterized by an XRPD pattern substantially the same as FIG. 8.

### Claim 14 (depends on 12)

The substantially crystalline compound of claim 12, wherein the compound of Formula (1)·HCl Form 2 is characterized by an XRPD pattern comprising one or more peaks chosen from peaks at about 8.00° 2θ, 10.11° 2θ, 11.98° 2θ, 13.33° 2θ, 14.40° 2θ, 14.92° 2θ, 15.66° 2θ, 16.05° 2θ, 16.72° 2θ, and 17.28° 2θ.

### Claim 15

The substantially crystalline compound of any one of the preceding claims, wherein the substantially crystalline compound is at least 85% crystalline.

### Claim 16

The substantially crystalline compound of any one of the preceding claims, wherein the substantially crystalline compound is at least 90% crystalline.

### Claim 17

The substantially crystalline compound of any one of the preceding claims, wherein the substantially crystalline compound is at least 95% crystalline.

### Claim 18

The substantially crystalline compound of any one of the preceding claims, wherein the substantially crystalline compound is at least 97% crystalline.

### Claim 19

The substantially crystalline compound of any one of the preceding claims, wherein the substantially crystalline compound is at least 99% crystalline.
